

Amendments to the Claims:

Please amend the claims as forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A kit, comprising *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV), particularly and/or salts thereof, and, physically separated therefrom, a base material of a pharmaceutical agent selected from the group comprising a tablet, a capsule, a coated tablet, a suppository, an ointment, a cream, a solution for infusion and/or injection, and optionally information relating to contacting the contents of the kit, said base materials being selected in such a way that, following contacting the *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) (*cis*-oxoplatin) with the base material,
 - the capsule comprises *cis*-oxoplatin : silicon dioxide : mannitol or magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
 - the tablet comprises *cis*-oxoplatin : lactose : corn starch : poly(O-carboxymethyl)starch sodium salt : calcium hydrogen phosphate \times 2H₂O : cellulose powder : magnesium stearate at a ratio of 10 to 500 : 20 to 150 : 1 to 10 : 1 to 10 : 1 to 10 : 0.1 to 7; or
 - the tablet alternatively comprises *cis*-oxoplatin : silicon dioxide : magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
 - the cream comprises *cis*-oxoplatin : benzyl alcohol : cetyl stearyl alcohol : Macrogol stearate 1000 : isopropyl palmitate : glycerol : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 0.1 to 7 : 1 to 10 : 0.1 to 7 : 0.1 to 7 : 0.2 to 8 : 0.2 to 8 : 20 to 60;
 - the ointment comprises *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl alcohol : vaseline at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400;
 - the gel comprises *cis*-oxoplatin : hydroxyethylcellulose : chloroaerosol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water at a ratio of 2 to 20 : 100 to 600 : 5 to 40 : 0.1 to 7 : 20 to 60 : 3,000 to 50,000;

- the suppository comprises *cis*-oxoplatin : silicon dioxide : hardened fat at a ratio of 0.1 to 10 : 0.1 to 10 : 30 to 300; or
 - the suppository alternatively comprises *cis*-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : highly dispersed silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 700 to 4,000 : 200 to 600 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 10; or
 - the suppository alternatively comprises *cis*-oxoplatin : lactose \times 1H₂O : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 1,000 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7; or
 - the suppository alternatively comprises *cis*-oxoplatin : lactose \times 1H₂O : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 1,000 : 1,500 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7;

2. (Previously Presented) The kit according to claim 1, wherein said kit is a chemotherapeutical kit.

3. (Cancelled)

4. (Currently Amended) A pharmaceutical agent comprising the components of the kit according to claim 1 *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) (*cis*-oxoplatin) and/or salts thereof, and a base material selected from a tablet, a capsule, a coated tablet, a suppository, an ointment, a cream or a solution for infusion and/or injection, wherein said base material and the *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) are:

- a capsule comprising *cis*- oxoplatin : silicon dioxide : mannitol or magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;

- a tablet comprising *cis*-oxoplatin : lactose : corn starch : poly(O-carboxymethyl)starch sodium salt : calcium hydrogen phosphate $\times 2\text{H}_2\text{O}$: cellulose powder : magnesium stearate at a ratio of 10 to 500 : 20 to 150 : 1 to 10 : 1 to 10 : 1 to 10 : 0.1 to 7;
 - a tablet comprising *cis*-oxoplatin : silicon dioxide : magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
 - a cream comprising *cis*-oxoplatin : benzyl alcohol : cetyl stearyl alcohol : Macrogol stearate 1000 : isopropyl palmitate : glycerol : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 0.1 to 7 : 1 to 10 : 0.1 to 7 : 0.1 to 7 : 0.2 to 8 : 0.2 to 8 : 20 to 60;
 - an ointment comprising *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl alcohol : vaseline at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400;
 - a gel comprising *cis*-oxoplatin : hydroxyethylcellulose : chloroaerosol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water at a ratio of 2 to 20 : 100 to 600 : 5 to 40 : 0.1 to 7 : 20 to 60 : 3,000 to 50,000;
 - a suppository comprising *cis*-oxoplatin : silicon dioxide : hardened fat at a ratio of 0.1 to 10 : 0.1 to 10 : 30 to 300;
 - a suppository comprising *cis*-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : highly dispersed silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 700 to 4,000 : 200 to 600 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 10;
 - a suppository comprising *cis*-oxoplatin : lactose $\times 1\text{H}_2\text{O}$: corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 1,000 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7;
 - a suppository comprising *cis*-oxoplatin : lactose $\times 1\text{H}_2\text{O}$: corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 1,000 : 1,500 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7;
 - a solution for injection or infusion comprising *cis*-oxoplatin : benzyl alcohol : Polysorbate 80 : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 1 to 10 : 0.1 to 7 : 100 to 800 : 100 to 400; or
 - a solution for injection or infusion comprising *cis*-oxoplatin : mannitol :

water at a ratio of 0.1 to 7 : 5 to 40 : 1 to 10.

5. (Previously Presented) The pharmaceutical agent according to claim 4, wherein

the capsule additionally comprises silicon dioxide and mannitol or silicon dioxide and magnesium stearate and/or pharmaceutically acceptable vehicles, especially siosomes, liposomes and/or nanocapsules.

6. (Previously Presented) The pharmaceutical agent according to claim 4, wherein

the capsule comprises 50 mg of silicon dioxide, 50 mg of mannitol or 50 mg of magnesium stearate and 50 mg of oxoplatin, or, alternatively, 50 mg of *cis*-oxoplatin, 39.5 mg of lactose or 39 mg, 2.5 mg or 2 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate $\times 2\text{H}_2\text{O}$, 2.5 mg of cellulose powder, and 0.5 mg of magnesium stearate, or, alternatively, 50mg of *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

7. (Previously Presented) The pharmaceutical agent according to claim 4, wherein

the capsule comprises 50 mg of silicon dioxide, 50 mg of mannitol or 50 mg of magnesium stearate and 50 mg of oxoplatin, or, alternatively, 50 mg of *cis*-oxoplatin, 39.5 mg of lactose or 39 mg, 2.5 mg or 2 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate $\times 2\text{H}_2\text{O}$, 2.5 mg of cellulose powder and 0.5 mg of magnesium stearate, or, alternatively, 50mg of *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

8. (Previously Presented) The pharmaceutical agent according to claim 4, wherein the cream comprises 50 mg of *cis*-oxoplatin, 20 mg of benzyl alcohol, 100 mg of cetyl stearyl alcohol, 25 mg of Macrogol stearate 1000, 20 mg of isopropyl palmitate, 40 mg of glycerol, 50 mg of sorbitol and 205 mg of water.

9. (Previously Presented) The pharmaceutical agent according to claim 4, wherein the ointment comprises 50 mg of *cis*-oxoplatin, 120 mg of propylene glycol, 5.5 mg

of Macrogol stearate 1000, 22 mg of cetyl stearyl alcohol, and 851.5 mg of vaseline.

10. (Previously Presented) The pharmaceutical agent according to claim 4, wherein the gel comprises 0.05 g of *cis*-oxoplatin, 1.8 g of hydroxyethylcellulose, 0.1 g of chloroaerosol, 0.005 g of sodium hydroxide, 0.17 g of sodium hydrogen phosphate dihydrate, and 97.875 g of water.

11. (Previously Presented) The pharmaceutical agent according to claim 4, wherein the suppository comprises 0.02 g of *cis*-oxoplatin, 0.02 g of silicon dioxide and 1.85 g of hardened fat, alternatively, that the suppository comprises 20 mg of *cis*-oxoplatin, 1055 mg of lactose, 170 mg of corn starch, 63.60 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80, alternatively, that the suppository comprises 20 mg of *cis*-oxoplatin, 1350 mg of lactose \times 1H₂O, 170 mg of corn starch, 65 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80, or, alternatively, that the suppository comprises 50 mg of *cis*-oxoplatin, 1450 mg of lactose \times 1H₂O, 170 mg of corn starch, 65 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80.

12. (Previously Presented) The pharmaceutical agent claim 4, wherein the preparation of a 5 mg/ml injection or infusion solution comprises 5 mg of *cis*-oxoplatin, 9 mg of benzyl alcohol, 2 mg of Polysorbate 80, 650 mg of 70% sorbitol solution and 500 mg of water.

13. (Previously Presented) The pharmaceutical agent according to claim 4, wherein the tablet comprises 50 mg of *cis*-oxoplatin, 39.5 mg of lactose, 2.5 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate \times 2H₂O, 2.5 mg of cellulose powder and 0.5 mg of magnesium stearate, or, alternatively, 50 mg of *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

14. (Cancelled)

15. (Previously Presented) A method of producing a pharmaceutical agent for the treatment of tumors comprising combining components of the kit of claim 1, wherein said *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) is incorporated in said base material prior to administration a patient.

16. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 4 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

17. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 6 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

18. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 7 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

19. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 8 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

20. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 9 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

21. (Previously Presented) A method for the prophylaxis or therapy of a

cancerous disease comprising administering the pharmaceutical agent of claim 10 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.

22. (Previously Presented) A method for the prophylaxis or therapy of a cancerous disease comprising administering the pharmaceutical agent of claim 11 to a person in need of such prophylaxis or therapy in a prophylactically or therapeutically effective amount.